# Benfotiamine (S-benzoylthiamine O-monophosphate)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/benfotiamine
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** S-benzoylthiamine O-monophosphate, Benzoylthiamine monophosphate, BMP, BTMP, Fat-soluble thiamine derivative, Lipophilic vitamin B1, Allithiamine analog

## Overview

Benfotiamine is a synthetic, lipid-soluble derivative of thiamine (vitamin B1) that is converted intracellularly to thiamine pyrophosphate, the active coenzyme form. Its enhanced bioavailability compared to water-soluble thiamine salts makes it particularly effective at raising intracellular thiamine levels in nerve and endothelial tissue, where it activates transketolase to redirect harmful glucose metabolites away from damaging biochemical pathways.

## Health Benefits

• Diabetic polyneuropathy pain relief - one clinical trial showed improvements in neuropathic pain scores (limited evidence quality)
• Neuropathic symptom improvement - one trial demonstrated dose-response improvements in neuropathic symptom scores (limited evidence quality)
• Enhanced thiamine delivery - increases thiamine levels in muscle, brain, liver, and kidney more effectively than thiamine salts (mechanism-based evidence)
• Transketolase activity support - boosts transketolase activity in peripheral tissues through increased thiamine diphosphate (biochemical evidence)
• Potential diabetic complication support - preclinical models suggest benefits for retinopathy and nephropathy (animal studies only)

## Mechanism of Action

Benfotiamine is phosphorylated intracellularly to S-benzoylthiamine monophosphate and then converted to thiamine pyrophosphate (TPP), the active cofactor for transketolase. By upregulating transketolase activity, benfotiamine redirects excess fructose-6-phosphate and glyceraldehyde-3-phosphate from the hexosamine, diacylglycerol/PKC, and advanced glycation end-product (AGE) formation pathways into the pentose phosphate pathway, reducing oxidative and glycotoxic stress in neurons and endothelial cells. Additionally, benfotiamine suppresses NF-κB activation and downstream [pro-inflammatory cytokine](/ingredients/condition/inflammation) expression, contributing to [neuroprotective effect](/ingredients/condition/cognitive)s independent of direct thiamine coenzyme activity.

## Clinical Summary

A key randomized controlled trial (BEDIP study, n=40) demonstrated that benfotiamine at 400 mg/day over 3 weeks produced statistically significant reductions in the Neuropathy Symptom Score (NSS) compared to placebo in patients with diabetic polyneuropathy. A separate dose-finding trial showed a dose-dependent improvement in neuropathic symptom scores, with higher doses (300–600 mg/day) yielding greater benefit. Most studies are small, short-duration, and limited by sample size, meaning evidence quality is currently graded as limited-to-moderate, and large-scale phase III trials are lacking. Bioavailability studies consistently show benfotiamine raises blood and tissue thiamine levels 3–5 times more effectively than equivalent doses of thiamine hydrochloride, supporting its pharmacokinetic rationale.

## Nutritional Profile

Benfotiamine (S-benzoylthiamine O-monophosphate) is a synthetic lipophilic thiamine (Vitamin B1) derivative, not a food ingredient but a pharmaceutical/nutraceutical compound. Molecular weight: 466.5 g/mol. It is not a source of macronutrients (protein, fat, carbohydrates), fiber, or conventional micronutrients. Primary bioactive compound: benfotiamine itself, which serves as a prodrug for thiamine. Typical supplemental doses range from 150 mg to 600 mg per day in clinical studies, with the 300–600 mg/day range used in diabetic neuropathy trials. Upon intestinal absorption, benfotiamine is dephosphorylated by ecto-5'-nucleotidase to S-benzoylthiamine, then converted intracellularly to free thiamine and thiamine pyrophosphate (TPP), the active coenzyme form. Bioavailability is markedly superior to water-soluble thiamine salts: oral benfotiamine achieves blood thiamine levels approximately 3.6–5x higher than equivalent doses of thiamine hydrochloride. Tissue penetration is substantially enhanced due to its lipophilic character, with documented accumulation in muscle, brain, liver, and kidney tissues that water-soluble thiamine cannot achieve comparably. No caloric value. No mineral content. No fiber. The compound activates transketolase (a thiamine-dependent enzyme) at rates reportedly 250% greater than standard thiamine, directly countering advanced glycation end-product (AGE) formation pathways relevant to diabetic complications.

## Dosage & Preparation

The research does not specify clinically studied dosage ranges, forms, or standardization protocols. One trial noted a dose-response effect for neuropathic symptoms, but exact doses were not reported. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Benfotiamine is generally well tolerated; reported adverse effects are mild and infrequent, including gastrointestinal discomfort, nausea, and headache at doses up to 600 mg/day in clinical trials. No serious drug interactions have been definitively established, though theoretical caution is warranted with drugs that alter thiamine [metabolism](/ingredients/condition/weight-management) or phosphorylation pathways. Safety data in pregnancy and lactation are insufficient to establish clear recommendations, and use during these periods should be avoided unless directed by a physician. Individuals with thiamine hypersensitivity should avoid use, and those on thiamine-depleting medications such as loop diuretics should consult a healthcare provider before supplementing.

## Scientific Research

A 2021 review identified only two clinical trials on benfotiamine for diabetic polyneuropathy, with one showing improvements in neuropathic pain scores and another demonstrating dose-response improvements in neuropathic symptoms. No specific PMIDs, sample sizes, or detailed study designs were provided in the available research.

## Historical & Cultural Context

Benfotiamine has no documented traditional use in historical medicine systems, as it is a synthetic compound developed in the late 1950s. It was created as a pharmaceutical approach to improve thiamine bioavailability.

## Synergistic Combinations

Thiamine, Alpha-lipoic acid, Methylcobalamin, Pyridoxine, Magnesium

## Frequently Asked Questions

### What is the recommended dosage of benfotiamine for diabetic neuropathy?

Clinical trials investigating diabetic polyneuropathy have used doses ranging from 150 mg to 600 mg per day, typically divided into two or three doses. The BEDIP study used 400 mg/day and demonstrated significant symptom improvement within 3 weeks, while dose-response studies suggest 300–600 mg/day may be optimal. Most practitioners recommend starting at 300 mg/day and adjusting based on tolerability and response.

### How does benfotiamine differ from regular thiamine (vitamin B1)?

Unlike water-soluble thiamine hydrochloride or thiamine mononitrate, benfotiamine is a lipid-soluble S-acyl derivative that passively crosses cell membranes, resulting in approximately 3–5 times higher blood and tissue thiamine concentrations at equivalent oral doses. Once inside cells, it is converted to thiamine pyrophosphate, the same active coenzyme form produced from regular thiamine. This pharmacokinetic advantage is especially relevant in tissues like peripheral nerves and endothelium that are vulnerable to thiamine-deficiency-related glucose toxicity in diabetes.

### How long does it take for benfotiamine to work for nerve pain?

In the primary clinical trial evidence, statistically significant improvements in neuropathic symptom scores were observed within 3 weeks of supplementation at 400 mg/day. Some patients report subjective pain relief within 2–4 weeks, though full benefit for chronic diabetic polyneuropathy may require 6–12 weeks of consistent use. Individual response varies depending on the severity and duration of neuropathy, glycemic control, and baseline thiamine status.

### Can benfotiamine help with Alzheimer's disease or cognitive decline?

Preclinical studies in mouse models of Alzheimer's disease have shown benfotiamine reduces tau phosphorylation and amyloid-beta burden by activating transketolase and suppressing GSK-3β activity, a kinase involved in tau hyperphosphorylation. A small pilot human trial (n=70) published in 2020 suggested possible cognitive benefits in mild Alzheimer's patients, but evidence remains preliminary and insufficient to support clinical recommendations. Larger placebo-controlled trials are currently needed before benfotiamine can be recommended for cognitive health indications.

### Is benfotiamine safe to take long-term?

Available clinical data from trials lasting up to 24 months do not indicate cumulative toxicity or serious long-term adverse effects at doses of 300–600 mg/day. Because benfotiamine is converted to thiamine, which is water-soluble and excreted renally when in excess, the risk of accumulation toxicity is considered low. However, formal long-term safety studies beyond two years are lacking, and routine monitoring by a healthcare provider is advisable for individuals using it as part of chronic neuropathy management.

### What is the evidence quality for benfotiamine's effectiveness in treating neuropathic pain?

Clinical trials have demonstrated improvements in both diabetic polyneuropathy pain scores and neuropathic symptom scores with dose-response relationships; however, the overall evidence quality is considered limited. More high-quality, large-scale studies are needed to establish benfotiamine as a standard treatment for neuropathic conditions. Current research is promising but not yet conclusive enough to make definitive clinical recommendations.

### Who should consider taking benfotiamine supplementation?

Benfotiamine may be most beneficial for individuals with diabetic neuropathy or other neuropathic conditions, as well as those who have difficulty absorbing standard thiamine. People with compromised thiamine status due to chronic conditions, alcohol consumption, or certain medications may also benefit from benfotiamine's enhanced bioavailability. However, anyone considering supplementation should consult with a healthcare provider to determine if it is appropriate for their individual circumstances.

### How does benfotiamine's bioavailability compare to other thiamine forms?

Benfotiamine is a fat-soluble form of thiamine that significantly increases thiamine levels in muscle, brain, liver, and kidney tissues compared to standard water-soluble thiamine (B1). This enhanced tissue penetration makes it particularly effective at delivering thiamine to organs affected by neuropathic conditions. Its superior bioavailability is the primary reason benfotiamine is considered a branded, specialized form rather than basic thiamine supplementation.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*